Management of Supraventricular Tachycardia (SVT)

Acute Management – Hemodynamically Unstable SVT

• Immediate synchronized cardioversion is the definitive treatment for unstable SVT (hypotension, altered mental status, shock, chest pain, acute heart failure) and restores sinus rhythm in essentially all patients while avoiding anti‑arrhythmic drug complications. – ACC/AHA guideline 1, 2, 3
• Initial shock energy should start at 50–100 J and be increased stepwise if conversion is not achieved. – ACC/AHA guideline 4
• A defibrillator must be readily available when attempting adenosine because adenosine can precipitate rapid‑ventricular‑response atrial fibrillation. – ACC/AHA guideline 1, 5

Acute Management – Hemodynamically Stable SVT

First‑Line Non‑Pharmacologic Maneuvers

• Modified Valsalva maneuver (patient supine, bearing down against a closed glottis for 10–30 s, generating ~30–40 mm Hg intrathoracic pressure) achieves conversion in ≈ 43 % of cases (≈ 28 % when combined with other maneuvers). – ACC/AHA guideline 1
• Carotid sinus massage (after confirming absence of bruit) applied for 5–10 s to either carotid sinus is an accepted adjunct. – ACC/AHA guideline 1, 6
• Diving reflex (application of an ice‑cold wet towel to the face) is an alternative vagal technique. – ACC/AHA guideline 1, 6
• Applying pressure to the eyeballs is contraindicated and should never be performed. – ACC/AHA guideline 1

Second‑Line Pharmacologic Therapy – Adenosine

• Adenosine is the drug of choice after failed vagal maneuvers, converting 90–95 % of AVNRT/AVRT episodes. – ACC/AHA guideline 1, 6
• Dosing protocol: 6 mg rapid IV push followed by a 20 mL saline flush; if no conversion within 1–2 min, give 12 mg rapid IV push.** – ACC/AHA guideline 4
• A defibrillator must be immediately available because adenosine can precipitate atrial fibrillation that may rapidly conduct to ventricular fibrillation. – ACC/AHA guideline 1, 5
• Transient side effects occur in ~30 % of patients but resolve within < 1 min. – ACC/AHA guideline 1
• Dose adjustments: reduce initial dose to 3 mg in patients on dipyridamole, carbamazepine, or with transplanted hearts; increase dose when the patient is taking theophylline or caffeine.** – ACC/AHA guideline 4
• Contraindicated in patients with asthma. – ACC/AHA guideline 4

Third‑Line Pharmacologic Therapy – Intravenous Calcium‑Channel Blockers (CCBs) or Beta‑Blockers

• IV diltiazem or verapamil achieve conversion in 64–98 % of cases and are preferred when beta‑blockers are not tolerated or after adenosine failure. – ACC/AHA guideline 2, 7
• Infusion over up to 20 min can lessen the risk of hypotension. – ACC/AHA guideline 2
• Contraindications: do not use CCBs if ventricular tachycardia or pre‑excited atrial fibrillation is possible, and avoid in systolic heart failure.** – ACC/AHA guideline 2, 3
• IV beta‑blockers are reasonable alternatives with an excellent safety profile, though slightly less effective than CCBs. – ACC/AHA guideline 2, 3, 7

Fourth‑Line Electrical Therapy – Synchronized Cardioversion

• When pharmacologic therapy fails or is contraindicated in stable patients, synchronized cardioversion (after adequate sedation) yields 80–98 % success. – ACC/AHA guideline 2, 5

Special Situation – Pre‑Excited Atrial Fibrillation (Wolff‑Parkinson‑White)

• Unstable pre‑excited AF requires immediate synchronized cardioversion. – ACC/AHA guideline 1, 8, 9
• Stable pre‑excited AF should be treated with ibutilide or IV procainamide; AV‑nodal blocking agents (adenosine, diltiazem, verapamil, digoxin) are contraindicated because they can enhance accessory‑pathway conduction and precipitate ventricular fibrillation. – ACC/AHA guideline 1, 5, 8

Chronic / Long‑Term Management

Catheter Ablation

• Catheter ablation is recommended as first‑line therapy for recurrent symptomatic SVT, with single‑procedure success rates of 94.3–98.5 %. – ESC guideline 10

Long‑Term Pharmacotherapy (when ablation is not performed)

• Oral beta‑blockers, diltiazem, or verapamil are effective for ongoing SVT control. – ACC/AHA guideline 2, 3
• Both diltiazem and verapamil are well‑tolerated alternatives to ablation. – ACC/AHA guideline 3
• Patients should be monitored for bradyarrhythmias and hypotension after initiation, and these agents should be avoided in systolic heart failure. – ACC/AHA guideline 3

Common Pitfalls & Safety Checks

• Never delay cardioversion in unstable patients to attempt pharmacologic conversion. – ACC/AHA guideline 2, 7
• Always have a defibrillator ready when administering adenosine due to the risk of precipitating dangerous atrial fibrillation. – ACC/AHA guideline 1, 5
• Avoid calcium‑channel blockers or beta‑blockers if there is any suspicion of pre‑excited atrial fibrillation or ventricular tachycardia. – ACC/AHA guideline 2, 3, 8
• Post‑conversion premature ventricular complexes can re‑initiate SVT; consider anti‑arrhythmic therapy to prevent recurrence. – ACC/AHA guideline 1, 5
• Amiodarone and digoxin are no longer recommended for acute narrow‑complex SVT management. – ESC guideline 10

Acute Management of Supraventricular Tachycardia (SVT)

Vagal Maneuvers (First‑Line for Hemodynamically Stable Patients)

Adenosine (Second‑Line Pharmacologic Therapy)

Calcium‑Channel Blockers (Third‑Line Pharmacologic Therapy)

Beta‑Blockers (Alternative Third‑Line Therapy)

Synchronized Cardioversion (Fourth‑Line for Stable Patients)

Catheter Ablation (First‑Line for Recurrent Symptomatic SVT)

Long‑Term Pharmacotherapy (When Ablation Is Not Performed)

Safety Considerations & Complications

Evidence‑Based Management of Neonatal Supraventricular Tachycardia (SVT)

Acute Post‑Conversion Assessment

• Successful conversion of a neonatal SVT episode with ice‑water facial immersion indicates that the infant was hemodynamically stable enough to attempt vagal maneuvers rather than immediate electrical cardioversion, as recommended by the American College of Cardiology. 14

First‑Line Maintenance Therapy

• Oral digoxin or propranolol are identified as the most commonly used first‑line agents for maintenance anti‑arrhythmic therapy in infants with SVT, according to the American Heart Association’s publication in Circulation. 15

Rescue Pharmacologic Intervention

• If SVT recurs and does not respond to repeat ice‑water vagal stimulation, the next recommended step is an intravenous adenosine bolus of 0.1 mg/kg (maximum 6 mg) administered rapidly, with a defibrillator immediately available, as outlined by the American College of Cardiology and the American Heart Association. 14, 15

Immediate Electrical Management for Hemodynamic Instability

• When an infant with SVT becomes hemodynamically unstable (e.g., hypotension, altered mental status, or shock), synchronized cardioversion at 0.5–1 J/kg should be performed without delay, per guidelines from the American College of Cardiology and the American Heart Association. 14, 16

Management of Supraventricular Tachycardia (SVT)

Pharmacologic Therapy

• Adenosine is the first‑line drug after failed vagal maneuvers, converting 90–95 % of AVNRT/AVRT episodes (American College of Cardiology recommendation) 17
• Intravenous diltiazem or verapamil achieve conversion in 64–98 % of SVT cases and are preferred when β‑blockers are not tolerated or after adenosine failure (American Heart Association/American College of Cardiology guideline) 18, 19
• Administering diltiazem or verapamil as an infusion over up to 20 minutes reduces the risk of hypotension (AHA/ACC) 18
• Intravenous β‑blockers are reasonable alternatives with an excellent safety profile, though slightly less effective than calcium‑channel blockers (ACC/JACC) 18, 19, 17

Contraindications & Safety Precautions

• Calcium‑channel blockers must not be used when ventricular tachycardia or pre‑excited atrial fibrillation is possible, and should be avoided in patients with systolic heart failure (ACC) 18, 19
• β‑blockers should also be avoided in the presence of suspected pre‑excited atrial fibrillation or ventricular tachycardia because they may precipitate ventricular fibrillation (ACC) 18, 19
• Applying pressure to the eyeballs is contraindicated due to risk of ocular injury (JACC) 17

Cardioversion

• Synchronized cardioversion after pharmacologic failure or contraindication in hemodynamically stable patients yields 80–98 % success (ACC/JACC) 18, 17
• In hemodynamically unstable SVT, immediate synchronized cardioversion is definitive and restores sinus rhythm in essentially all patients (AHA/ACC) 18, 19

Long‑Term Management (When Ablation Is Not Performed)

• Oral β‑blockers, diltiazem, or verapamil are effective for ongoing SVT control in patients who decline or are unsuitable for catheter ablation (ACC/JACC) 18, 17
• Both diltiazem and verapamil are well‑tolerated pharmacologic alternatives to ablation (JACC) 17
• Patients started on these agents should be monitored for bradyarrhythmias and hypotension, and the drugs should be avoided in the setting of systolic heart failure (JACC) 17

Management of Supraventricular Tachycardia (SVT) in Patients with Shock

Contraindication of Metoprolol in Shock

• Metoprolol is contraindicated in patients who present with both shock and SVT; the definitive treatment for hemodynamically unstable SVT is immediate synchronized cardioversion rather than beta‑blocker therapy. 20

Immediate Synchronized Cardioversion

• Synchronized cardioversion should be performed without delay in any patient with SVT who is in shock, and pharmacologic agents should not be administered first. [20][21]
• Hemodynamic instability (shock) is defined by the presence of hypotension, altered mental status, clinical signs of poor perfusion, chest pain, or acute heart failure. Recognizing these criteria triggers the cardioversion pathway. 20
• Vagal maneuvers and adenosine are reserved for stable, regular, narrow‑complex SVT; they should not be attempted when shock is present. 20
• Adequate sedation should be provided before cardioversion if the patient’s mental status allows, but sedation must not postpone the procedure. [20][21]

Use of Intravenous Beta‑Blockers in Stable SVT

• Intravenous beta‑blockers are appropriate only in hemodynamically stable patients with SVT, typically as a third‑line option after failure of vagal maneuvers and adenosine. [20][21]22
• The ACC/AHA guidelines explicitly state that IV beta‑blockers should be used “only in hemodynamically stable patients” and note that their efficacy is inferior to that of calcium‑channel blockers for rate control. [21][22]

Safety Considerations

• Negative inotropes (beta‑blockers or calcium‑channel blockers) must never be used for rate control in patients who are already hypotensive or in shock, as they further depress cardiac output and tissue perfusion. 20

Common Pitfall to Avoid

• The most dangerous error is attempting pharmacologic rate control before recognizing hemodynamic instability; when any sign of shock is present, immediate synchronized cardioversion is the sole appropriate intervention. 20

Management of Supraventricular Tachycardia

Hemodynamically Unstable SVT

• Immediate synchronized cardioversion restores sinus rhythm in essentially all patients and avoids drug‑related complications; defibrillation equipment should be ready because cardioversion is nearly 100 % effective. 23, 24
• Sedation may be given only if it does not postpone the cardioversion. 24
• Vagal maneuvers or adenosine should not be attempted before cardioversion. 23

Hemodynamically Stable SVT – First‑Line Vagal Maneuvers

• Modified Valsalva maneuver – patient supine, bear down against a closed glottis for 10–30 seconds generating ≥30–40 mm Hg intrathoracic pressure. 24, 23
• Carotid sinus massage – first auscultate for carotid bruit; then apply steady pressure over one carotid sinus for 5–10 seconds. 23, 24
• Diving reflex – apply an ice‑cold wet towel to the face. 24

Adenosine (Second‑Line Pharmacologic Therapy)

• Adenosine converts 90–95 % of AVNRT and AVRT episodes. 24
• A defibrillator must be immediately available because adenosine can precipitate atrial fibrillation with rapid ventricular response or ventricular fibrillation. 24
• Transient side effects occur in ≈30 % of patients but resolve within 1 minute. 24

Calcium‑Channel Blockers and Beta‑Blockers (Third‑Line Therapy)

• Intravenous diltiazem or verapamil achieve conversion in 64–98 % of cases; infusion should be slow (up to 20 minutes) to minimize hypotension. 23
• Calcium‑channel blockers must not be used when ventricular tachycardia or pre‑excited atrial fibrillation is possible, as they can precipitate ventricular fibrillation. 23
• Calcium‑channel blockers are contraindicated in systolic heart failure. 23
• Intravenous beta‑blockers (e.g., metoprolol, esmolol) are a reasonable alternative with an excellent safety profile and should be used only in hemodynamically stable patients. 23

Synchronized Cardioversion (Fourth‑Line for Stable Patients)

• If pharmacologic therapy fails or is contraindicated, perform synchronized cardioversion after adequate sedation; success rate is 80–98 %. 23, 24

Pre‑Excited Atrial Fibrillation (Wolff‑Parkinson‑White)

• In unstable patients, immediate synchronized cardioversion is mandatory because rapid accessory‑pathway conduction can cause ventricular fibrillation. 24
• In stable patients, use ibutilide or intravenous procainamide to slow accessory‑pathway conduction; never use AV‑nodal blockers (adenosine, diltiazem, verapamil, beta‑blockers, digoxin) as they may enhance accessory‑pathway conduction and precipitate ventricular fibrillation. 24

Chronic Pharmacologic Management

• Oral beta‑blockers, diltiazem, or verapamil provide effective long‑term rhythm control; avoid calcium‑channel blockers in patients with systolic heart failure. 23

Safety Precautions

• A defibrillator must always be ready when administering adenosine. 24
• Post‑conversion monitoring is essential because premature ventricular complexes can re‑initiate SVT. 24

Adenosine Use in Undifferentiated Rapid Rhythms

Guideline Recommendations

• The 2015 ACC/AHA/HRS guideline gives a Class I recommendation (Level B‑NR) for using adenosine in regular narrow‑complex tachycardias even when the exact mechanism (SVT vs. atrial fibrillation) is uncertain, because it provides both therapeutic and diagnostic benefits, such as unmasking atrial flutter or atrial tachycardia. 25
• The 2010 AHA ACLS guideline reinforces that adenosine should be considered the first‑line agent for regular narrow‑complex tachycardia, and may be used before cardioversion in unstable patients when the rhythm is regular and narrow. 26

Safety Profile & Contraindications

• Adenosine’s very short half‑life (<10 seconds) makes serious adverse effects rare; transient symptoms (chest discomfort, shortness of breath, flushing) typically resolve within one minute. Class I, Level B‑NR evidence supports its safety in this context. 25
• A defibrillator must be immediately available because adenosine can precipitate atrial fibrillation with rapid ventricular response in about 12 % of patients, especially those with Wolff‑Parkinson‑White (WPW) syndrome. 26
• Contraindicated in:
  • Suspected pre‑excited atrial fibrillation (WPW with AF) – AV‑node blockade may enhance accessory‑pathway conduction and precipitate ventricular fibrillation. Class III, Level C. 27
  • Patients with asthma, high‑grade AV block without a pacemaker, or sinus node dysfunction. Class III, Level C. 26

Patient Selection & Hemodynamic Considerations

• Hemodynamically unstable patients (hypotension, altered mental status, shock, chest pain, acute heart failure) should receive immediate synchronized cardioversion; adenosine is not indicated. Class I, Level B‑NR. 25
• For regular narrow‑complex tachycardia in a stable patient, adenosine is safe and appropriate (Class I). 25
• In irregular narrow‑complex tachycardia (likely atrial fibrillation), adenosine may transiently slow the ventricular rate for diagnostic purposes but will not terminate the rhythm; rate‑control agents (β‑blocker or calcium‑channel blocker) are preferred. Class IIa, Level C. 26
• With wide‑complex tachycardia where differentiation between VT and SVT with aberrancy is uncertain, adenosine can be used diagnostically provided a defibrillator is ready. Class IIb, Level C. 28

Pre‑Administration Checks

• Screen for pre‑excitation (delta waves on prior ECGs or a very short PR interval during tachycardia). If pre‑excitation is possible, avoid adenosine and proceed directly to cardioversion or procainamide. 26
• Confirm defibrillator availability at the bedside and ensure continuous ECG monitoring before drug administration. 26

Administration Technique

• Initial dose: 6 mg rapid IV push through a large proximal vein (e.g., antecubital) followed immediately by a 20 mL saline flush. Class I, Level C. 26
• If no conversion within 1–2 minutes: give a second dose of 12 mg using the same rapid push and flush technique. Class I, Level C. 26
• Continuous ECG recording during the push is essential to distinguish true failure to terminate from transient termination with immediate re‑initiation. Class I, Level B‑NR. 25

Evidence Quality & Regulatory Perspective

• The 2015 ACC/AHA/HRS guideline (Class I, Level B‑NR) is the highest‑quality source supporting adenosine use in undifferentiated regular narrow‑complex tachycardias. 25
• The FDA label warns of rare but serious complications (cardiac arrest, sustained ventricular tachycardia, myocardial infarction, stroke, seizures); however, these events are exceedingly rare when proper precautions (defibrillator readiness, monitoring) are observed. Class IIb, Level C. 25

Acute and Chronic Management of Atrioventricular Nodal Reentrant Tachycardia (AVNRT)

1. Acute Termination Strategies

• Modified Valsalva maneuver (supine position, 10–30 s bearing down to generate ~30–40 mm Hg) converts approximately 43 % of AVNRT episodes. [American College of Cardiology/American Heart Association] [29]
• Carotid sinus massage (after confirming absence of carotid bruit) and ice‑water facial immersion are acceptable alternative vagal maneuvers. [American College of Cardiology/American Heart Association] [29]
• Adenosine is the first‑line pharmacologic agent after failed vagal maneuvers; a 6 mg rapid IV push (followed by a saline flush) converts 90–95 % of AVNRT episodes, with a repeat 12 mg dose if needed. [American College of Cardiology/American Heart Association] [29]
• Safety requirement for adenosine: a defibrillator must be immediately available because adenosine can precipitate atrial fibrillation with rapid ventricular response or ventricular fibrillation. [American College of Cardiology/American Heart Association] [29]
• Transient side effects (flushing, chest discomfort, dyspnea) occur in roughly 30 % of patients but resolve within one minute. [American College of Cardiology/American Heart Association] [29]

2. Pharmacologic Alternatives (Second‑Line)

• Intravenous diltiazem or verapamil achieve conversion in 64–98 % of cases and are considered equally effective as adenosine but with significantly fewer adverse effects; infusion should be administered over up to 20 minutes to limit hypotension. [American College of Cardiology/American Heart Association] [29]
• European Society of Cardiology (2020) recommendation: verapamil and diltiazem remain effective options but are downgraded in the acute AVNRT algorithm. [European Society of Cardiology] [30]
• Intravenous β‑blockers are reasonable alternatives with an excellent safety profile, though their efficacy is slightly lower than that of calcium‑channel blockers. [American College of Cardiology/American Heart Association] [29]
• Contraindications: calcium‑channel blockers and β‑blockers must not be used when ventricular tachycardia or pre‑excited atrial fibrillation is possible, and they should be avoided in patients with systolic heart failure. [American College of Cardiology/American Heart Association] [29] [European Society of Cardiology] [31]

3. Electrical Cardioversion

• Synchronized cardioversion (after adequate sedation) succeeds in 80–98 % of hemodynamically stable patients when pharmacologic therapy fails or is contraindicated. [American College of Cardiology/American Heart Association] [29] [American College of Cardiology/American Heart Association] [32]
• Unstable patients (hypotension, altered mental status, shock, chest pain, acute heart failure) require immediate synchronized cardioversion without preceding drug attempts. [American College of Cardiology/American Heart Association] [33] [American College of Cardiology/American Heart Association] [29]

4. Chronic / Long‑Term Management

4.1 Catheter Ablation

• Slow‑pathway catheter ablation is the preferred first‑line therapy for recurrent symptomatic AVNRT, with single‑procedure success rates of 94.3–98.5 % and minimal procedural risk. [European Society of Cardiology] [30] [American College of Cardiology/American Heart Association] [29]
• ESC 2019/2020 guidance recommends offering catheter ablation as the initial choice for most patients because of its high efficacy and limited benefit of long‑term antiarrhythmic drugs. [European Society of Cardiology] [30]

4.2 Pharmacologic Maintenance (when ablation is not performed)

• Oral verapamil or diltiazem are well‑tolerated maintenance options. [American College of Cardiology/American Heart Association] [29]
• Oral β‑blockers are also effective for ongoing rate control. [American College of Cardiology/American Heart Association] [29]
• Monitoring: watch for bradyarrhythmias and hypotension after initiation; avoid these agents in patients with systolic heart failure. [American College of Cardiology/American Heart Association] [29]
• ESC 2020 downgrades amiodarone, flecainide, propafenone, sotalol, and “pill‑in‑the‑pocket” strategies for chronic AVNRT; they are no longer recommended. [European Society of Cardiology] [30]

5. Safety Considerations & Common Pitfalls

• Defibrillator readiness is mandatory whenever adenosine is administered due to the risk of precipitating dangerous atrial fibrillation. [American College of Cardiology/American Heart Association] [33] [American College of Cardiology/American Heart Association] [29]
• Post‑conversion monitoring is essential because premature ventricular complexes can trigger recurrence; consider short‑term antiarrhythmic therapy to prevent acute re‑initiation. [American College of Cardiology/American Heart Association] [33] [American College of Cardiology/American Heart Association] [29]
• Pre‑excitation screening (e.g., delta waves on prior ECGs) should be performed before using AV‑nodal blocking agents. [European Society of Cardiology] [30] [American College of Cardiology/American Heart Association] [31]
• Agents to avoid in pre‑excited atrial fibrillation (WPW with AF): adenosine, calcium‑channel blockers, β‑blockers, digoxin, and amiodarone, as they may enhance accessory‑pathway conduction and precipitate ventricular fibrillation. [European Society of Cardiology] [30] [American College of Cardiology/American Heart Association] [31]
• Verapamil or diltiazem should not be used in wide‑QRS tachycardias of unknown origin. [European Society of Cardiology] [30]

6. Pregnancy Considerations

• First‑line therapy in pregnant patients remains vagal maneuvers and adenosine. [European Society of Cardiology] [30]
• β‑1‑selective blockers (excluding atenolol) or verapamil may be used cautiously in women without WPW; however, all antiarrhythmic drugs should be avoided during the first trimester when possible. [European Society of Cardiology] [30]